Stay updated with breaking news from Mark Bleackley. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Medicinal cannabinoid and psychedelic therapies developer Incannex Healthcare (ASX: IHL) has commenced a Phase 2 clinical trial to assess the safety and efficacy of its proprietary anti-inflammatory combination drug IHL-675A in patients with rheumatoid arthritis.
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has achieved an interim milestone for the PsiGAD1 clinical trial assessing the effect of psilocybin-assisted...
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has engaged multinational contract development and manufacturing organisation (CDMO) Eurofins Scientific to...
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has engaged multinational contract development and manufacturing organisation (CDMO) Eurofins Scientific to...
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has engaged Eurofins Scientific, a multinational contract development and manufacturing organisation, to...